Literature DB >> 3038429

Side effects and metabolic effects of converting-enzyme inhibitors.

M G Nicholls.   

Abstract

Side effects of angiotensin converting enzyme (ACE) inhibitors are not common with currently recommended doses. Hypotension, hyperkalemia and renal impairment may occur under special circumstances, and relate directly to blockade of ACE, in particular when pre-treatment renin levels are high. Other adverse effects, once quite common when excessive doses of captopril were prescribed, are now rarely seen. A possible exception is cough. Though not dangerous, cough is not infrequently seen during treatment with ACE inhibitors. Experience with these drugs is insufficient to recommend their use in the hypertension of pregnancy. The "metabolic-profile" with ACE inhibitors appears favourable, since they can increase uric acid excretion and lower plasma urate levels, carbohydrate tolerance is unaltered or improved, and lipid levels are unchanged. Electrolyte and metabolic effects of thiazide diuretics are blunted by addition of an ACE inhibitor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038429     DOI: 10.3109/10641968709164238

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  5 in total

Review 1.  Antihypertensive medications and depression.

Authors:  M H Beers; L J Passman
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Life-threatening hyperkalaemia in an elderly patient receiving captopril, furosemide (frusemide) and potassium supplements.

Authors:  T Y Chan; J A Critchley
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 4.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

5.  Assessment of ondansetron-associated hypokalemia in pediatric oncology patients.

Authors:  Elsa Fiedrich; Vikram Sabhaney; Justin Lui; Maury Pinsk
Journal:  ISRN Oncol       Date:  2012-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.